Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma

Authors

Julia Wendler,[1] Richard I. Lewis,[2,3] Alexandra Kutilina,[4] Markus Knott,[1] Lisa Kristina Isbell,[4] Elke Valk,[5] Peter Borchmann,[2,3] Jan-Michel Heger,[2,3,6#] Gerald Illerhaus[1#] and Elisabeth Schorb[4#]

[1]Clinic of Hematology, Oncology, Stem Cell Transplantation and Palliative Care, Klinikum Stuttgart, Stuttgart; [2]Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne; [3]Cologne Lymphoma Working Group (CLWG), Cologne; [4]Department of Medicine I, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg; [5]Stuttgart Cancer Center - Tumorzentrum Eva Mayr-Stihl, Stuttgart and [6]Mildred Scheel School of Oncology Aachen Bonn Cologne Düsseldorf (MSSO ABCD), Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany

#JMH, GI and ES contributed equally as senior authors.

Correspondence:
J. WENDLER - j.wendler@klinikum-stuttgart.de

https://doi.org/10.3324/haematol.2024.286347

Received: July 26, 2024.
Accepted: January 13, 2025.
Early view: January 23, 2025.

©2025 Ferrata Storti Foundation
Published under a CC BY-NC license

Supplementary Material

Supplementary Figures (SF)

SF 1 Subsequent treatment regimen following rituximab/high-dose methotrexate. A) Proportion of patients receiving respective treatment regimen; B) number of patients ultimately proceeding to ASCT



MATRix=high-dose methotrexate, high-dose cytarabine, thiotepa, rituximab; MARTA=high-dose methotrexate; high-dose cytarabine, rituximab; R-MP=rituximab, high-dose methotrexate, procarbazine, R-MTX=rituximab, high-dose methotrexate; BSC=best supportive care

SF 2 Occurrence of severe (≥ grade 3) infections. Grade ≥3 infections yes versus no following rituximab/high-dose methotrexate in regard to: A) total dose of dexamethasone; B) total duration of corticosteroid treatment; and C) time of corticosteroid treatment after rituximab/high-dose methotrexate initiation for n=83 patients that received initial corticosteroid treatment



mg=milligrams; d=day(s); R-MTX=rituximab/high-dose methotrexate; CTCAE=Common Terminology Criteria for Adverse Events

SF 3 Progression-free survival following pre-phase with rituximab/high-dose methotrexate. Progression-free survival in regard to: A) central nervous system lymphoma type; B) combined frailty score; C) subsequent induction treatment regimen; D) Autologous stem cell transplantation versus no autologous stem cell transplantation and overall survival in regard to E) central nervous system lymphoma type; F) combined frailty score; G) subsequent induction treatment regimen; H) Autologous stem cell transplantation versus no autologous stem cell transplantation



PCNSL=primary central nervous system lymphoma; SCNSL=secondary central nervous system lymphoma; MATRix=high-dose methotrexate, high-dose cytarabine, thiotepa, rituximab; MARTA=high-dose methotrexate; high-dose cytarabine, rituximab; PRIMAIN=rituximab, high-dose methotrexate, procarbazine; ASCT=autologous stem cell transplantation